Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.48 |
| ▸ | RAMP3 | O60896 | 8/20 | 0.47 |
| ▸ | CALCR | P30988 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593282 | 0.92 | OPRL1 (0.55) | OPRL1 | |
| SCHEMBL31255673 | 0.88 | CXCR4 (0.55) | RAMP3CALCR | |
| SCHEMBL31419692 | 0.86 | CXCR4 (0.55) | RAMP3CALCR | |
| SCHEMBL31593279 | 0.85 | RAMP3 (0.47) | RAMP3CALCR | |
| SCHEMBL31593262 | 0.85 | CXCR4 (0.62) | — | |
| SCHEMBL29380215 | 0.84 | RAMP3 (0.53) | RAMP3CALCR | |
| SCHEMBL30094613 | 0.83 | OPRL1 (0.50) | OPRL1 | |
| Parasin I SCHEMBL29412266 | 0.82 | OPRL1 (0.52) | OPRL1 | |
| SCHEMBL30432612 | 0.82 | RAMP3 (0.56) | RAMP3CALCR | |
| SCHEMBL30455559 | 0.82 | RAMP3 (0.61) | RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | OPRL1 2847/4885RAMP3 3434/4885CALCR 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.